Bristol Myers Squibb Boosts Drug Output 40% With AI
Bristol Myers Squibb reported approximately 40% volume growth in drug production at its Massachusetts facility, covering both clinical-trial supply and commercial manufacturing, attributed to AI-driven process optimization. The facility was highlighted as a bright spot in US manufacturing output.
Why It Matters
A 40% production increase at a major pharmaceutical facility from AI optimization is among the highest productivity figures reported in the AI-for-manufacturing category. It shifts the AI-in-pharma narrative from drug discovery to manufacturing scale — a less-discussed but economically significant application with direct implications for drug availability and supply-chain resilience.